High Efficiency Single Cell Cloning Of iPSCs Using Combination Of MatriClone™ And VIPS™

Induced pluripotent stem cells (iPSCs) have become a major focus in nearly all disease areas and a vehicle for future therapeutic especially when combined with gene editing technologies.

As the interest in the therapeutic value of iPSCs accelerates, so does the need to establish the regulatory framework and best practice in this area. Cell line development workflows using CHO cell types are well established in the production of monoclonal antibodies. In this area, there is a widely accepted regulatory expectation to use single cell cloning. By starting from a defined source cell variability, drift and ultimately product quality is best managed. For iPSCs, it is logical to explore methods to manage quality and overcome existing process hurdles by developing robust seeding and evidence of clonality methodologies.

There will be increasing needs for standardization in the generation of clonal iPSC Master Cell Banks. This will be true for gene edited cell lines in research through to the generation of iPSC therapeutic cell lines. VIPS is a well-established commercial platform for generation and documentation of clonal cells lines for CHO and HEK.

We review this effective turnkey solution for generating significantly more viable iPSC clones per plate along with image documentation for their clonal derivation.